📋 Tender Overview
Merck a leading science and technology company today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Mercks continued investment in novel modalities and support the companys efforts to double its ADC and high-potent active pharmaceutical ingredient HPAPI capacity in the near future.ADCs have experienced remarkable growth with commercially approved ADCs tripling in the past three years said Andrew Bulpin head of Process Solutions Life Science at Merck. We are a pioneer in this space involved in 50 percent of the commercially approved ADCs on the market today. This latest innovation and additional capacity help bring novel treatments to cancer patients around the world and reinforce our commitment to shaping the future of these novel modalities.With the launch of its ChetoSensar technology Merck is one of the front runners working to address the hydrophobicity of ADCs in tandem with its CDMO services. Many ADC candidates have poor aqueous solubility and Merck estimates that more than 20 percent of ADC clinical terminations are caused by this issue. The companys new ChetoSensar technology improves ADC solubility therefore giving hope to ADCs that were previously terminated.The payloads commonly used for ADCs are highly-complex molecules that take many steps to synthesize. Based on Mercks calculations its new DOLCORE platform significantly reduces the development and manufacturing time required increasing speed-to-market for a novel Dolostatin-based ADC payload by up to a year.In addition the company will enhance the ADC capabilities of its clinical manufacturing facility in St. Louis Missouri USA in December. This facility will provide larger footprint to enable large-scale production including chromatographic purification for early phase clinical supply. This follows last years announcement of a 59 million expansion of Mercks facility near Madison Wisconsin USA which will double its HPAPI kilo lab capacity and enable the company to expedite the manufacture of HPAPIs ADC linkerpayloads and complex APIs.This innovation and additional capacity support the companys ambition to accelerate growth through investments in the Big Three including the Process Solutions business unit within the Life Science business sector as a key driver. With 15 years of experience developing and manufacturing ADCs Merck offers unique CDMO services streamlined with a single highly experienced provider. The company leverages its global network and deep expertise to tailor each molecules unique journey while creating the dynamic client partnerships drug manufacturers need to help reach their critical milestones. Merck integrates contract development and manufacturing with the industrys broadest product offering across multiple modalities. Customers can also seamlessly integrate BioReliance services from the companys leading biosafety testing portfolio. Merck recently announced expansion projects in Darmstadt Germany Cork Ireland Buchs Switzerland Carlsbad California USA Madison Wisconsin USA Jaffrey New Hampshire USA and Danvers Massachusetts USA. These expansions are part of an ambitious multi-year program to increase the industrial capacity and capabilities of the Life Science business sector to support growing global demand for lifesaving medications and to make significant contributions to public health.